ArticleBMC cancer2019

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program.

Markus Moehler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.